Journal of Interventional Cardiology / 2019 / Article / Tab 2

Clinical Study

Gender-Related Differences in Clinical Characteristics and Outcomes of Premature Coronary Artery Disease: Insight from the FOCUS Registry

Table 2

Lesion characteristics: male versus female.

Variables TotalMaleFemalep value
(n=1997)(n=1237)(n=760)

Target vessel
 LM44 (2.2%)33 (2.7%)11 (1.4%)0.071
 LAD957 (47.9%)570 (46.1%)387 (50.9%)0.035
 LCX441 (22.1%)271 (21.9%)170 (22.4%)0.810
 RCA548 (27.4%)359 (29.0%)189 (24.9%)0.043
Lesion class
 Type A342 (17.1%)179 (14.5%)163 (21.4%)<0.001
 Type B1446 (22.3%)283 (22.9%)163 (21.4%)0.456
 Type B2355 (17.8%)235 (19.0%)120 (15.8%)0.069
 Type C853 (42.7%)539 (43.6%)314 (41.3%)0.322
Complex lesions
 Total occlusive lesion262 (13.1%)196 (15.8%)66 (8.7%)<0.001
 CTO92 (4.6%)62 (5.0%)30 (3.9%)0.270
 Acute total occlusive lesion170 (8.5%)134 (10.8%)36 (4.7%)<0.001
 Ostial lesion177 (8.9%)108 (8.7%)69 (9.1%)0.790
 Bifurcation lesion325 (16.3%)207 (16.7%)118 (15.5%)0.478
 Severe calcification lesion19 (1.0%)10 (0.8%)9 (1.2%)0.401
 Small vessel lesion566 (28.3%)293 (23.7%)273 (35.9%)<0.001
 Long lesion692 (34.7%)428 (34.6%)264 (34.7%)0.950
Lesion characteristics
 Lesion length (mm)27.5 ± 16.427.7 ± 16.627.3 ± 16.10.603
 Reference diameter(mm)2.9 ± 0.43.0 ± 0.52.9 ± 0.4<0.001
 Lesion diameter stenosis (%)86.6 ± 10.587.3 ± 10.785.6 ± 10.10.001
Stent characteristics
 Stent implanted per lesion1.2 ± 0.51.2 ± 0.51.2 ± 0.50.955
 Stent length (mm)24.4 ± 6.924.6 ± 7.024.2 ± 6.90.007
 Stent diameter (mm)3.0 ± 0.93.1 ± 0.82.9 ± 1.10.319

Values are presented as mean ± SD or n (percentage). Small vessel is defined as the diameter of the vessel ≤ 2.5 mm. Long lesion is defined as the total length of the lesion ≥ 30 mm.
CTO: chronic total occlusion; LAD: left anterior descending artery; LCX: left circumflex artery; LM: left main artery; MCAD: mature coronary artery disease; PCAD: premature coronary artery disease; and RCA: right coronary artery.
p≤0.001, p≤0.01, and p≤0.05.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.